Teplizumab – preventative approaches to type 1 diabetes mellitus

Teplizumab Preserves C-Peptide in Recent-Onset Type 1 Diabetes

Protégé was a phase 3, randomized, double-blind, parallel, placebo-controlled 2-year study of three intravenous teplizumab dosing regimens, administered daily for 14 days at baseline and again after 26 weeks, in new-onset type 1 diabetes. We sought to determine efficacy and safety of teplizumab immunotherapy at 2 years and to identify characteristics associated with therapeutic response. Of 516...

Type 1 diabetes mellitus.

1. All children with type 1 diabetes mellitus (T1DM) should have their blood sugar managed with basal-bolus insulin treatment by either multiple daily injections or an insulin pump. 2. All children with T1DM should have access to a pediatric endocrinologist with a diabetes management team with resources to support patients and families. 3. All children with T1DM should be monitored for symptoms...

Complementary and Alternative Medicine to Treat Diabetes Mellitus Type 1 in Southern Iran

type 1 diabetes mellitus & gluten induced disorders

over the last five decades the association between coeliac disease and other autoimmune disorders such as autoimmune thyroid disease or diabetes mellitus type 1 has been well established through many studies and to this day is subject to on-going clinical and scientific investigation worldwide. while no link has been established between coeliac disease and type 2 diabetes mellitus, coeliac dise...

New Approaches to the Immunotherapy of Type 1 Diabetes Mellitus Using Interleukin-27.

Type 1 diabetes (T1D) is a pancreatic beta cell specific autoimmune disease. One of the most significant current discussions in T1D studies is therapy. Since the conventional therapy, islet transplantation and external insulin, e.g., cannot prevent the destructive autoimmune process against original beta cells and persistent hyperglycemia remains, so recent developments in the field of T1D ther...